Connection between caffeine, adenosine receptors and dopamine: Coffee reduces the risk of Parkinson's disease;Samband mellan koffein, adenosinreceptorer och dopamin: Kaffe minskar risk för Parkinsons sjukdom

Lakartidningen

Volumn 101, Issue 34, 2004, Pages 2552-2555

  Fredholm, Bertil B ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR; CAFFEINE; DOPAMINE;

BASAL GANGLION; COFFEE; GLOBUS PALLIDUS; HUMAN; PARKINSON DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION;

ANIMALS; BASAL GANGLIA; CAFFEINE; COFFEE; HUMANS; PARKINSON DISEASE; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE D2;

EID: 4544312030     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999;51:83-153.
2. Salazar-Martinez E, Willett WC, Ascherio A, Manson JE, Leitzmann MF, Stampfer MJ, et al. Coffee consumption and risk for type 2 diabetes mellitus. Ann Intern Med 2004;140(1):1-8.
3. Schwarzschild MA, Xu K, Oztas E, Petzer JP, Castagnoli K, Castagnoli N, et al. Neuroprotection by caffeine and more specific A(2A) receptor antagonists in animal models of Parkinson's disease. Neurology 2003;61(11 Suppl 6):S55-61.
4. Fredholm BB, Svenningsson P. Adenosine-dopamine interactions - development of a concept and some comments on therapeutic possibilities. Neurology 2003;61(Suppl 6):5-9.
5. Fuxe K, Ungerstedt U. Action of caffeine and theophyllamine on supersensitive dopamine receptors: considerable enhancement of receptor response to treatment with DOPA and dopamine receptor agonists. Med Biol 1974;52:48-54.
6. Fredholm BB, Fuxe K, Agnati L. Effect of some phosphodiesterase inhibitors on central dopamine mechanisms. Eur J Pharmacol 1976;38:31-8.
7. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz K-N, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53(4):527-52.
8. Svenningsson P, Le Moine C, Fisone G, Fredholm BB. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog Neurobiol 1999;59:355-96.
9. Ferré S, von Euler G, Johansson B, Fredholm BB, Fuxe K. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc Natl Acad Sci U S A 1991;88:7238-41.
10. Svenningsson P, Nomikos GG, Fredholm BB. Biphasic changes in locomotor behavior and in expression of mRNA for NGFI-A and NGFI-B in rat striatum following acute caffeine administration. J Neurosci 1995;15:7612-24.
11. Svenningsson P, Fourreau L, Bloch B, Fredholm BB, Gonon F, Le Moine C. Opposite tonic modulation of dopamine and adenosine on c-fos mRNA expression in striatopallidal neurons. Neuroscience 1999;89:827-37.
12. Svenningsson P, Lindskog M, Ledent C, Parmentier M, Greengard P, Fredholm BB, et al. Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine Di, dopamine D2 and adenosine A2A receptors. Proc Natl Acad Si U S A 2000;97:1856-60.
13. Gerfen CR. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci 1992;15:285-320.
14. Fall PA, Fredrikson M, Axelson O, Granérus AK. Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden. Mov Disord 1999;14(1):28-37.
15. Hernán MA, Takkouche B, Caamaño-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002;52(3):276-84.
16. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000;283(20):2674-9.
17. Ascherio A, Zhang SM, Hernán MA, Kawachi I, Colditz GA, Speizer FE, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001;50(1):56-63.
18. Schwarzschild MA, Chen JF, Ascherio A. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. Neurology 2002;58(8):1154-60.
19. Herrera-Marschitz M, Casas M, Ungerstedt U. Caffeine produces contralateral rotation in rats with unilateral dopamine denervation: comparisons with apomorphine-induced responses. Psychopharmacology (Berl) 1988;94(1):38-45.
20. Chen JF, Moratalla R, Impagnatiello F, Grandy DK, Cuellar B, Rubinstein M, et al. The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc Natl Acad Sci U S A 2001;98(4):1970-5.
21. Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001;21(10):RC143.
22. Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 2003;60(5):790-5.